CAS: 141-84-4; 2-Thioxothiazolidin-4-One

上下游产品

CAS号6326-83-6 双(羧甲基)三硫代碳酸盐 | CAS号79-11-8 氯乙酸 | CAS号14064-10-9 氯代丙二酸二乙酯 | CAS号513-74-6 二硫代氨基甲酸铵 | CAS号75-15-0 二硫化碳 | CAS号556-90-1 假硫代乙内酰脲 | CAS号79-04-9 氯乙酰氯 | CAS号29596-83-6 2-carbamothioyl... | CAS号107916-92-7 (5E)-2-疏基-5-(2-... | CAS号105769-26-4 5-[(4-phenoxyph... | CAS号1078-50-8 4-Thiazolidinon... | CAS号4807-55-0 3-甲基罗丹宁 | CAS号20949-66-0 2-(甲硫基)-1,3-噻唑-... | CAS号16781-67-2 2-吗啉-4-基-1,3-噻唑... | CAS号534-13-4 N,N′-二甲基硫脲 | CAS号37530-35-1 (5E)-5-(3-羟基亚苄基... | CAS号4120-64-3 (5E)-2-疏基-5-(4-... | CAS号217316-44-4 (5E)-5-(2-氯-6-氟...

2-硫氰酸基乙酸乙酯置于乙醇,硫化氢体系中,化学反应生成罗丹宁
参考文献:Miolati,Justus Liebigs Annalen Der Chemie,1891,Vol. 262,P. 79
标题:Miolati,Justus Liebigs Annalen Der Chemie,1891,Vol. 262,P. 79

专利信息

专利号:US-6159673-A
优先权日:1996-07-17
标 题:Oxonol compound, light-sensitive material and process for the synthesis of oxonol compound
发明人：NISHIGAKI JUNJI; DEGUCHI YASUAKI
权利人:FUJI PHOTO FILM CO LTD
摘要:An oxonol compound is represented by the following formula (I): in which Z is an atomic group that forms a cyclic amide ring; each of W1 and W2 independently is an atomic group that forms an acidic nucleus ring; and M is a cation. Other oxonol compounds, a light-sensitive material containing an oxonol compound and a process for the synthesis of an oxonol compound are also disclosed.

专利号:EP-1473330-B1
优先权日:1996-07-17
标题:Process for the synthesis of oxonol compound
发明人：NISHIGAKI JUNJI; DEGUCHI YASUAKI
权利人:FUJI PHOTO FILM CO LTD
摘要:An oxonol compound is represented by the following formula (I): in which each of Z, W<1> and W<2> independently is an atomic group that forms a heterocyclic ring; and M is a cation. A process for the synthesis of an oxonol compound is disclosed.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-2005239808-A1
优先权日:2002-05-10
标题 :Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
发明人：SCHRADER THOMAS; RIESNER DETLEV; RZEPECKI PETRA; NAGEL-STEGER LUITGARD; WEHNER MARK; KIRSTEN CHRISTIAN; MOLT OLIVER; ZADMARD REZA; ASCHERMANN KATJA
权利人:SCHRADER THOMAS; RIESNER DETLEV; RZEPECKI PETRA; NAGEL-STEGER LUITGARD; WEHNER MARK; KIRSTEN CHRISTIAN; MOLT OLIVER; ZADMARD REZA; ASCHERMANN KATJA
摘要:The invention on hand refers to diseases associated with abnormal protein structures, including Alzheimer's disease, Creutzfeldt-Jakob's disease, BSE and other prion-associated diseases. It is the task of the invention on hand to provide new active agents preventing the formation of amyloid plaques and to dissolve existing plaques, such agents being convenient for therapy, diagnosis and prophylaxis of diseases that are associated with abnormal protein structures. This task is performed in terms of the current invention by heterocyclic or aromatic agents with a rigid structure and a donor-acceptor-donor pattern (DAD), the latter being formed by donors and acceptors of hydrogen bridge linkages which comply with the β-sheet structure of the peptide or protein and thus fit as binding partners. The heterocyclic or aromatic agents are available at least as dimers. They recognise peptides and proteins with a β-sheet structure, form stable complexes with them and inhibit their aggregation to β-amyloid plaques. Furthermore, the new active agents are able to dissolve β-amyloid plaques that already exist. Another task of the current invention is to provide methods for the synthesis of said heterocyclic or aromatic compounds.

专利号:US-5872124-A
优先权日:1996-07-31
标题 :Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
发明人：KOPROWSKI HILARY; HOOPER DOUGLAS CRAIG; FARBER JOHN L
权利人:UNIV JEFFERSON
摘要:The process of treating a disease of the central nervous system with an agent from one or more of the following three classes of agents: (1) nitric oxide scavengers, (2) peroxynitrite scavengers, and (3) agents that either interfere with the synthesis of iNOS in the cell or the enzymatic activity of iNOS in the cell.

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人：MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.